Copyright
©The Author(s) 2023.
World J Virol. Sep 25, 2023; 12(4): 233-241
Published online Sep 25, 2023. doi: 10.5501/wjv.v12.i4.233
Published online Sep 25, 2023. doi: 10.5501/wjv.v12.i4.233
Table 2 Baseline demographic and clinical characteristics of the study population
| Characteristic | HBV patient group | HCV patient group |
| Patients, n | 99 | 87 |
| Sex as M/F ratio | 3.34:1.00 | 1.71:1.00 |
| Age in yr, mean ± SD | 44.0 ± 14.6 | 46.0 ± 14.9 |
| Total bilirubin in mg/dL, median (IQR) | 0.83 (0.59-0.83) | 0.95 (0.58-2.15) |
| Direct bilirubin in mg/dL, median (IQR) | 0.18 (0.10-0.47) | 0.25 (0.10-0.62) |
| ALT values in IU/mL, median (IQR) | 32.5 (23.2-60.1) | 33 (17.0-59.7) |
| AST values in IU/mL, median (IQR) | 36 (28.00-62.75) | 46 (27.0-99.2) |
| NeuMoDx viral load as log10 IU/mL, median (IQR) | 2.9 (2.0-4.3) | 4.9 (4.2-5.4) |
| COBAS viral load as log10 IU/mL, median (IQR) | 3.7 (2.28-4.56) | 5.1 (4.07-5.80) |
- Citation: Chooramani G, Samal J, Rani N, Singh G, Agarwal R, Bajpai M, Kumar M, Prasad M, Gupta E. Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load. World J Virol 2023; 12(4): 233-241
- URL: https://www.wjgnet.com/2220-3249/full/v12/i4/233.htm
- DOI: https://dx.doi.org/10.5501/wjv.v12.i4.233